...
首页> 外文期刊>Drug discovery today >How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals.
【24h】

How developing world concerns need to be part of drug development plans: a case study of four emerging antiretrovirals.

机译:发展中国家如何关注需要成为药物开发计划的一部分:一项针对四种新兴抗逆转录病毒药物的案例研究。

获取原文
获取原文并翻译 | 示例
           

摘要

Clinical trials are usually designed to meet registration requirements in developed countries, and do not always address key concerns for use in developing countries. Four late-stage investigational new drugs - rilpivirine, etravirine, raltegravir and maraviroc - show potential to improve antiretroviral therapy. However, a number of issues could limit their use in developing countries, including dose selection, treatment strategy, combination with other drugs, use in specific populations and reliance on expensive tests. Key research questions relevant for developing countries need to be answered early in the drug development process to ensure maximum benefit for the majority.
机译:临床试验通常旨在满足发达国家的注册要求,并不总是解决在发展中国家使用的关键问题。四种晚期试验性新药-利匹韦林,依曲韦林,拉格韦和马拉维罗克-具有改善抗逆转录病毒疗法的潜力。但是,许多问题可能会限制它们在发展中国家的使用,包括剂量选择,治疗策略,与其他药物的组合,在特定人群中的使用以及对昂贵测试的依赖。与发展中国家有关的关键研究问题需要在药物开发过程中尽早回答,以确保大多数人获得最大利益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号